









Markets
/
Stocks
/
nasdaq-bngo
/

Bionano Genomics Inc

BNGO

1.790USD

0.000

Close 09/19, 16:00（ET）Quotes delayed by 15 min

7.00MMarket Cap

LossP/E TTM



Bionano Genomics Inc

1.790

0.000

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a strong stock market performance, the company shows strong fundamentals and technicals, which don't support the current strong trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

137 / 207

Overall Ranking

360 / 4720

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

9.500

Target Price

+430.73%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Bionano Genomics, Inc. is a genomics company. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. Through Lineagen, Inc., the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).

Growing

The company is in a growing phase, with the latest annual income totaling USD 30.78M.

Overvalued

The company’s latest PE is -0.00, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 352.54K shares, decreasing 15.10% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 0.00 shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 5.97, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 6.73M, representing a year-over-year decrease of 13.36%, while its net profit experienced a year-over-year decrease of 57.74%.

Score

Industry at a Glance

Previous score

5.97

Change



Financials

5.33

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.14

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

5.22

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.05

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Healthcare Equipment & Supplies industry's average of 3.59. Its current P/E ratio is -0.00, which is 33333.33% below the recent high of -0.10 and -240833.33% above the recent low of -0.72.

Score

Industry at a Glance

Previous score

2.80

Change

1.2

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 137/207

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 7.33, which is lower than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Bionano Genomics Inc is 9.50, with a high of 11.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

7.33

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

9.500

Target Price

+430.73%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Bionano Genomics Inc

BNGO

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Intuitive Surgical Inc

ISRG

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 1.94, which is lower than the Healthcare Equipment & Supplies industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 4.36 and the support level at 0.36, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.94

Change

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.607

Sell

RSI(14)

29.988

Sell

STOCH(KDJ)(9,3,3)

7.856

Oversold

ATR(14)

0.549

High Vlolatility

CCI(14)

-107.660

Sell

Williams %R

92.750

Oversold

TRIX(12,20)

-0.739

Sell

StochRSI(14)

4.341

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.980

Sell

MA10

3.140

Sell

MA20

3.530

Sell

MA50

3.361

Sell

MA100

3.494

Sell

MA200

5.536

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 10.48%, representing a quarter-over-quarter increase of 13.48%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Geode Capital Management, L.L.C.

15.51K

-6.75%

Parametric Portfolio Associates LLC

11.49K

BlackRock Institutional Trust Company, N.A.

10.10K

-0.04%

BofA Global Research (US)

8.39K

+41865.00%

Osaic Holdings, Inc.

3.21K

+1722.73%

UBS Financial Services, Inc.

1.91K

-1.14%

Group One Trading, L.P.

1.79K

-59.47%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.94, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 2.26. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.